Japan Digestive Disease Week 2025
International Poster Session3 (JDDW)
October 31, 9:30–10:18, Room 15 (Kobe International Exhibition Hall No.1 Building Digital Poster Venue)
IP-13_E
Risk Factors for Rebleeding after Trans-Arterial Embolization in Patients with Non-Variceal Upper Gastrointestinal Bleeding Travel Award
- 1
- Division of Gastroenterology, Bundang Jesaeng General Hospital
- 2
- Department of Gastroenterology, Cha Gangnam Medical Center, Cha University of School of Medicine
Non-variceal upper gastrointestinal bleeding (NVUGIB) is usually controlled endoscopically, but failure can be life-threatening. Trans-arterial embolization (TAE) is a less invasive, effective rescue therapy, as an alternative to surgery. Identifying rebleeding risk factors may improve management.
This retrospective study analyzed 167 patients who underwent TAE (January 2008–June 2023) after emergent endoscopy. Rebleeding was defined as melena, hematemesis, or hematochezia with hemoglobin drop (>0.8 g/dL) or shock. The primary outcome was 30-day rebleeding.
Among 104 NVUGIB patients, 24 (23.1%) experienced rebleeding within a month after TAE. They had higher thrombocytopenia (50.0% vs. 15.0%, p=0.001), coagulopathy (20.8% vs. 5.0%, p=0.045), AIMS65 score (2.0 vs. 1.0, p=0.029), ABC score (7.0 vs. 4.0, p=0.002), and 7-day mortality (16.7% vs. 2.5%, p=0.035).
Multivariate analysis identified thrombocytopenia (OR: 5.44, p=0.002) and ABC score ≥6 (OR: 2.87, p=0.005) as independent risk factors.
TAE could be an effective and safe treatment for NVUGIB. However, thrombocytopenia and elevated ABC scores may increase the risk of 30-day rebleeding, necessitating close monitoring for safer and more efficient management.
This retrospective study analyzed 167 patients who underwent TAE (January 2008–June 2023) after emergent endoscopy. Rebleeding was defined as melena, hematemesis, or hematochezia with hemoglobin drop (>0.8 g/dL) or shock. The primary outcome was 30-day rebleeding.
Among 104 NVUGIB patients, 24 (23.1%) experienced rebleeding within a month after TAE. They had higher thrombocytopenia (50.0% vs. 15.0%, p=0.001), coagulopathy (20.8% vs. 5.0%, p=0.045), AIMS65 score (2.0 vs. 1.0, p=0.029), ABC score (7.0 vs. 4.0, p=0.002), and 7-day mortality (16.7% vs. 2.5%, p=0.035).
Multivariate analysis identified thrombocytopenia (OR: 5.44, p=0.002) and ABC score ≥6 (OR: 2.87, p=0.005) as independent risk factors.
TAE could be an effective and safe treatment for NVUGIB. However, thrombocytopenia and elevated ABC scores may increase the risk of 30-day rebleeding, necessitating close monitoring for safer and more efficient management.
As no diagrams are provided here, please refer to each academic journal of structure and member societies.
- Index Term 1: non variceal upper gastrointestinal bleeding
- Index Term 2: embolization